Merck & Co., Inc. (MRK)

Check out top investors' recommendation for MRK
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
253.20
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
90%/10%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. It offers human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of cardiovascular, diabetes and obesity, respiratory, women's health and endocrine, inflammatory and infectious diseases, oncology, ophthalmology, and others. The company also provides vaccines, including preventive pediatric, adolescent, and adult vaccines. In addition, it discovers, develops, manufactures, and markets animal health products comprising vaccines, antibiotics, and anti-inflammatory drugs for respiratory diseases, as well as products for the treatment of fertility disorders. Further, the company manufactures and sells over-the-counter products consisting of non-drowsy antihistamines; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant spray; and products for occasional constipation and frequent heartburn. Additionally, it offers foot care products, including topical antifungal, and foot and sneaker odor/wetness products; and sun care products, such as sun care lotions, sprays, and dry oils. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, food chain and mass merchandiser outlets, club stores, and specialty channels, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. It has a collaboration with Sanofi Pasteur S.A. and Abide Therapeutics, Inc.; and has a collaboration and license agreement with Luminex Corporation. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Jason Gerberry Leerink Swann Llc Buy   Nov 28, '17     64.00  Nov 28, '18  N/A 
Tim Anderson High Peaks Buy   Nov 15, '17     64.00  Nov 15, '18  N/A 
Marc Goodman UBS Buy   Oct 30, '17     67.00  Oct 30, '18  N/A 
Chris Schott JPMorgan Buy   Oct 27, '17     70.00  Oct 27, '18  N/A 
Richard Purkiss Atlantic Equities Buy   Oct 26, '17     70.00  Oct 26, '18  N/A 
Charles Graham Unaffiliated Buy   Oct 21, '17     1000.00  Nov 21, '17  N/A 
Michael Yee RBC Capital Markets Sell   Oct 20, '17     55.00  Oct 20, '18  N/A 
Andrew Baum Citi Buy   Oct 18, '17     72.00  Oct 18, '18  N/A 
Alex Arfaei BMO Capital Markets Buy   Oct 11, '17     70.00  Oct 11, '18  N/A 
Charles Graham Unaffiliated Buy   Sep 28, '17     1000.00  Sep 28, '18  N/A 
Alex Arfaei BMO Capital Markets Buy   Sep 08, '17     72.00  Sep 08, '18  N/A 
Michael Yee RBC Capital Markets Sell   Aug 18, '17     52.00  Aug 18, '18  N/A 
Richard Purkiss Atlantic Equities Buy   Jul 28, '17     70.00  Jul 28, '18  N/A 
John Boris Citi Buy   Jul 28, '17     73.00  Jul 28, '18  N/A 
Alex Arfaei BMO Capital Markets Buy   Jul 28, '17     73.00  Jul 28, '18  N/A 
Michael Yee RBC Capital Markets Sell   Jul 17, '17     52.00  Jul 17, '18  N/A 
Alex Arfaei BMO Capital Markets Buy   Jun 27, '17     74.00  Jun 27, '18  N/A 
Andy Barish Jefferies & Co. Sell   May 24, '17     51.00  May 24, '18  N/A 
Dave Shove BMO Capital Markets Buy   May 11, '17     74.00  May 11, '18  N/A 
Dave Shove BMO Capital Markets Buy   Mar 21, '17     70.00  Mar 21, '18  N/A 
< previous1234